|Year : 2016 | Volume
| Issue : 1 | Page : 64-66
A rare cause of bifascicular block: Daunorubicin induced cardiotoxicity
Prakas Kumar Mandal, Meet Kumar, Maitryee Bhattyacharyya
Department of Hematology, NRS Medical College, Kolkata, West Bengal, India
|Date of Web Publication||2-Jun-2016|
Prakas Kumar Mandal
8C/1/N, Roy Para Road, Kolkata - 700 050, West Bengal
Source of Support: None, Conflict of Interest: None
Anthracyclines are indispensable for acute leukemia management and known to have immediate as well as late cardiac effects. Among the immediate effects, commonly described effects include arrhythmias and repolarization abnormalities. We report a rare electrocardiographic presentation of daunorubicin toxicity.
Keywords: Bifascicular block, cardiotoxicity, daunomycin, management
|How to cite this article:|
Mandal PK, Kumar M, Bhattyacharyya M. A rare cause of bifascicular block: Daunorubicin induced cardiotoxicity. Arch Med Health Sci 2016;4:64-6
|How to cite this URL:|
Mandal PK, Kumar M, Bhattyacharyya M. A rare cause of bifascicular block: Daunorubicin induced cardiotoxicity. Arch Med Health Sci [serial online] 2016 [cited 2019 Jun 20];4:64-6. Available from: http://www.amhsjournal.org/text.asp?2016/4/1/64/183356
| Introduction|| |
Anthracyclines are an indispensable part of acute leukemia management today. However, they are associated with significant adverse effects. The first report that showed the cardiotoxic potential of anthracyclines was published by Ainger et al . Here, we report a rare electrocardiographic presentation of daunorubicin-induced cardiotoxicity.
| Case Report|| |
A 26-year-old female presented with complains of weakness and low-grade fever for last 1½ months. She also complained of gum bleeding ad menorrhagia for last 15 days. On examination, she had pallor and multiple bleeding spots all over the body including wet purpura. Her complete blood count and peripheral blood smear examination showed hemoglobin 67 g/L, total leukocyte count 13.4 × 109/L with 91% circulating blasts, and platelet count 12 × 109/L. Immunophenotyping results showed cells in the blast window to be positive for MPO, CD117, CD13, CD15, CD33, CD19, and human leukocyte antigen-DR suggestive of acute myeloid leukemia with aberrant CD19. Cytogenetics showed 46XX, t(8;21) (q21;q22) and del (9q13-22) in all metaphases. Blood biochemistries and serum electrolytes were within normal limits. A baseline electrocardiogram (ECG) [Figure 1] and echocardiography were normal. She was started on standard “3 + 7” induction chemotherapy with daunorubicin (60 mg/m 2 daily for 3 days) and Ara-C (cytarabine at 200 mg/m 2 as continuous infusion for 7 days). On the 2nd day, she complained of mild giddiness and nonspecific headache. On examination, she had pulse rate of 58/min, that was regular. Blood pressure was 110/70 mm of Hg. An ECG showed the development of a new bifascicular block [Figure 2]. The cardiotoxicity profile of all the drugs the patient was receiving was reviewed and serum electrolytes and troponin-T done, which were noncontributory. Echocardiography was unremarkable. Her ECG changes reverted back to normal after almost 12 h. Last dose of daunorubicin was delayed for 1 week followed by serial ECG, all showing normal tracings.
|Figure 1: baseline (prechemotherapy) electrocardiogram showing normal pattern|
Click here to view
|Figure 2: postchemotherapy (day 2 of daunorubicin), electrocardiogram showing bifascicular block|
Click here to view
| Discussion|| |
Anthracyclines are known to have immediate as well as late cardiac effects. The majority of these toxic effects are due to direct cell damage. Free radical–mediated myocyte damage is one of the most thoroughly studied mechanisms by which anthracyclines have been proposed to cause cardiotoxicity. The ECG changes associated with anthracyclines include nonspecific changes in ST segment and T-wave, sinus tachycardia, supraventricular, and ventricular premature beats., A bifascicular block on ECG is defined by the combination of a right bundle branch block and a left anterior or posterior fascicular block. When these occur in combination, significant conduction disease is usually present, and there is a risk for higher degrees of atrioventricular block in the future causing symptomatic bradycardia, requiring pacemaker implantation., The 2009 ACC/AHA scientific statement on ECG interpretation does not recommend the use of the terms “bifascicular” or “trifascicular”, but they are quite commonly used. ECG is among recommended diagnostic methods for detection of cardiotoxicity in oncology. It is a widely available and low-cost examination.
Acute or sub-acute form of cardiotoxicity may occur immediately after a single dose or a course of anthracycline therapy, with clinical manifestations occurring within a week of treatment. These may be in the form of transient electrophysiological abnormalities., ECG changes may be seen in 20-30% of the patients. Sinus tachycardia is the most common rhythm disturbance. Arrhythmias, including ventricular, supraventricular, and junctional tachycardia, are seen in 0.5-3% of patients.
In the present study, the patient presented with bradycardia, that on ECG showed a bifascicular block, which has not been reported previously. Furthermore, the fascicular block which recovered spontaneously after discontinuation of the drug and without administration of any specific therapy. Even on re-administration of daunorubicin, as is recommended for such cases, no recurrence was noticed., The present case identified an uncommon ECG finding, and it highlights the significance of keeping a high index of suspicion for cardiac morbidity for patients being treated with anthracyclines.
| Conclusion|| |
Early detection of anthracycline-induced cardiotoxicity could significantly reduce the development of clinical manifestations. Simple and low-cost diagnostic methods, for example, ECG is very helpful for detection of cardiotoxicity in hematooncology. Re-administration of daunorubicin under close supervision is recommended for such cases.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Ainger LE, Bushore J, Johnson WW, Ito J. Daunomycin: A cardiotoxic agent. J Natl Med Assoc 1971;63:261-7.
Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: The need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010;102:14-25.
Doroshow JH. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 1983;43:460-72.
Horacek JM, Jakl M, Horackova J, Pudil R, Jebavy L, Maly J. Assessment of anthracycline-induced cardiotoxicity with electrocardiography. Exp Oncol 2009;31:115-7.
Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, et al.
Cardiovascular complications of cancer therapy: Diagnosis, pathogenesis, and management. Circulation 2004;109:3122-31.
Hampton J. The ECG Made Easy. 7th
ed. Oxford, UK: Elsevier Publishing; 2008.
Surawicz B, Childers R, Deal BJ, Gettes LS. ACC/AHA recommendations for the standardization and interpretation of the electrocardiogram. Circulation 2009;119:e235-40.
Shakir DK, Rasul KI. Chemotherapy induced cardiomyopathy: Pathogenesis, monitoring and management. J Clin Med Res 2009;1:8-12.
Frishman WH, Sung HM, Yee HC, Liu LL, Keefe D, Einzig AI, et al.
Cardiovascular toxicity with cancer chemotherapy. Curr Probl Cancer 1997;21:301-60.
Al-Ismail SA, Parry DH, Whittaker JA. Anthracycline cardiotoxicity and acute myelogenous leukaemia. Br Med J 1977;1:815.
[Figure 1], [Figure 2]